SCHEMBL992833

SCHEMBL992833

NCc1ccc(Cl)cc1F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.44
HTR2A P28223 3/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
LOXL2 Q9Y4K0 2/20 0.42
TP53 P04637 1/20 0.41
HTR1A P08908 1/20 0.41
HTR7 P34969 1/20 0.41
HTR6 P50406 1/20 0.41
IDO1 P14902 3/20 0.41
PNMT P11086 3/20 0.40
CXCR3 P49682 1/20 0.40
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP2C19 P33261 1/20 0.39
TAAR1 Q96RJ0 2/20 0.38
TRPM8 Q7Z2W7 1/20 0.38
GRM2 Q14416 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30474185 1.00 CYP2A6 (0.44) CYP2A6HTR2AHTR2CHTR2BLOXL2
Hydrochloric Acid SCHEMBL5957928 0.98 HTR2A (0.46) CYP2A6HTR2AHTR2CHTR2BLOXL2
SCHEMBL4392149 0.84 TAAR1 (0.50) HTR2AHTR2CHTR2BTP53HTR1A
SCHEMBL29876674 0.84 CYP2A6 (0.46) CYP2A6HTR2AHTR2CHTR2BLOXL2
SCHEMBL1765267 0.84 CYP2A6 (0.46) CYP2A6HTR2AHTR2CHTR2BLOXL2
Hydrochloric Acid SCHEMBL16401793 0.83 TAAR1 (0.48) HTR2AHTR2CHTR2BTP53HTR1A
SCHEMBL30970546 0.83 HTR2A (0.41) HTR2AHTR2CHTR2BTP53HTR1A
Bromide SCHEMBL15741801 0.82 CYP2A6 (0.44) CYP2A6HTR2AHTR2CHTR2BLOXL2
SCHEMBL4604208 0.81 KMT2A (0.48) HTR2ATP53HTR1AHTR7HTR6
SCHEMBL6194409 0.81 CHEK1 (0.41) HTR2AHTR2CHTR2BTP53HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3077380-B1 THIENOMETHYLPIPERAZINE DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE SANOFI SA (FR) 2018-07-25 EP claimed
EP-2681215-B1 SERINE/THREONINE KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-04-22 EP claimed
US-8729089-B2 Pyrido(3,2-d)pyrimidines useful for treating viral infections GILEAD SCIENCES, INC. (US) 2014-05-20 US claimed
EP-1812004-B1 ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS ASTEX THERAPEUTICS LTD (GB) 2011-06-22 EP claimed
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-31 US claimed
WO-2008077651-A1 PYRIDO(3,2-D)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS GILEAD SCIENCES, INC. (US) 2008-07-03 WO claimed
EP-1611121-B1 PYRIDAZINONE DERIVATIVES AS CDK2-INHIBITORS AVENTIS PHARMA SA (FR) 2007-08-08 EP claimed
EP-1581505-B1 PYRIDAZINONE DERIVATIVES AS GSK-3BETA INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2007-08-01 EP claimed
WO-2026102082-A1 ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-15 WO disclosed
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-14 US disclosed
US-20260035362-A1 GLP-1R AGONISTS AND USES THEREOF QILU REGOR THERAPEUTICS INC (CN) 2026-02-05 US disclosed
EP-4635568-A2 COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES ACADIA Pharmaceuticals Inc. (US) 2025-10-22 EP disclosed
US-20250289787-A1 HERBICIDAL 2-OXO-NICOTINIC ACID DERIVATIVES SYNGENTA CROP PROTECTION AG (CH) 2025-09-18 US disclosed
EP-3672954-B1 COMPOUNDS, SALTS THEREOF AND THEIR USE FOR THE TREATMENT OF DISEASES ACADIA PHARM INC (US) 2025-08-13 EP disclosed
CN-1036564-C Herbicidal glutarmides ROHM & HAAS (US) 1997-12-03 CN disclosed
US-5631209-A ALGICIDES ROHM AND HAAS COMPANY (US) 1997-05-20 US disclosed
US-5502027-A ALGICIDES ROHM AND HAAS COMPANY (US) 1996-03-26 US disclosed
EP-0415642-B1 Glutarimides ROHM & HAAS (US) 1995-12-06 EP disclosed
US-5393735-A N-(halo-oxy-)phenyl substituted cyclic imides ROHM AND HAAS COMPANY (US) 1995-02-28 US disclosed
EP-0415642-A1 Glutarimides ROHM AND HAAS COMPANY (US) 1991-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035362-A1 GLP-1R AGONISTS AND USES THEREOF GLP1R, GPR119, IAPP CYP2A6 3119/4885HTR2A 1546/4885HTR2C 1375/4885
US-20250289787-A1 HERBICIDAL 2-OXO-NICOTINIC ACID DERIVATIVES DDT, NQO2, NAPRT CYP2A6 190/4885HTR2A 1607/4885HTR2C 1828/4885
US-20260132119-A1 Alkylphenyl Substituted Compounds, Compositions and Methods of Use GIPR, MC2R, GRPR CYP2A6 134/4885HTR2A 1090/4885HTR2C 195/4885
US-20080182870-A1 PYRIDO(3,2-d)PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS PNPO, DPYD, PNP CYP2A6 134/4885HTR2A 1032/4885HTR2C 489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.